Cancer Drug

Will not invest in R&D of medicines in India: Novartis chairman

Drug major Novartis warned that Supreme Court's rejection of its patent plea for cancer drug Glivec will discourage future innovation in India and pointed out that the company has never been granted an original patent for Glivec in the country.

Novartis patent case: Five facts about the cancer drug Glivec

Glivec has been a major breakthrough invention of the 20th century for the treatment of cancer. Here are five things you should know about the drug.

Boost for cheaper drugs: SC rejects Novartis patent on Glivec

A decision in the seven-year legal battle is keenly awaited by the two most interested parties- big pharma companies and health aid groups - with both sides saying the outcome will set a precedent with far-reaching consequences for the future availability of the drugs.

India rejects AstraZeneca's patent protection plea on cancer drug

<br /><br /> The decision is a setback for struggling AstraZeneca, which is battling to turn itself around as key drugs lose patent protection.

Why don't you reduce cancer drug price, SC asks Novartis

Pharma major Novartis AG Tuesday said it was the author of beta crystalline, a form of a compound used in an anti-cancer drug, while the Supreme Court asked the company why it could not reduce its medicine's price.